John Rex, MD, FACP, discusses the promise, precision, and challenges of this first-in-class antifungal following phase 2b trial results.
John Rex, MD, FACP
Advertisement
Chief Medical Officer at F2G
Articles by John Rex, MD, FACP
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Contagion Live
1
Antibiotic De-Escalation Demonstrates Advantages for Community-Onset Sepsis
2
Vigilance, Training, and Funding are Key for Outbreak and Pandemic Biopreparedness
3
Addressing the Three Pillars of PPE in Caring for Patients with High-Consequence Infectious Disease
4
Top Infectious Disease News Stories Week of December 20 - December 26
5